In my understanding Prana had given Bohlmann L et al group PBT2...

In my understanding Prana had given Bohlmann L et al group PBT2 to study it but Prana knew nothing about the results neither that their report was sent to a journal to be published. Thanks to HeadSet reading medical news bulletin and reporting these Prana news here on our board, I sent  the abstract to Prana and they did not know anything of these results. But now they know ( Kempler and Stamler) , but even now no reaction. Yesterday Kempler was not in the office when I phoned to Prana and Stamler was most likely still sleeping in San Francisco. So it is not very quick to respond news. 
Prana is a small company but a public company. They need to act very carefully and so it may take a bit time. Perhaps they need to talk first with the Bohlmann group, then to keep some kind of a meeting about what to do etc.  This will change "the Sinclair deal", in fact this news can help Prana to get a lot of more money what is now planned with Sinclair. 

This paper by Bahlmann et al is IMO a "Nobel prize"  paper. Perhaps they did not want to have any Prana people as authors but they gave however credit to PBT2 as Prana's drug (????).  Think what WHO Director-General told about present antibiotics, "On current trends, common diseases may become untreatable. Doctors facing patients will have to say, Sorry, there is nothing I can do for you."  In any case this paper is very valuable to the authors, to Prana and in fighting severe infections.